Table 5.
Adverse events.
| Parameters | DEB-TACE group (N = 31) | cTACE group (N = 40) | p-value |
|---|---|---|---|
| Liver abscess (n/%) | 0 (0.0) | 1 (2.5) | 1.000 |
| Increase of ascites (n/%) | 3 (9.7) | 4 (10.0) | 1.000 |
| Fever (n/%) | 10 (32.3) | 23 (57.5) | 0.034 |
| Moderate pain (VAS ≥4) (n/%) | 6 (19.4) | 8 (20.0) | 0.946 |
| CINV grade (n/%) | |||
| 0 | 8 (25.8) | 3 (7.5) | 0.001 |
| I | 14 (45.2) | 9 (22.5) | |
| II | 6 (19.4) | 17 (42.5) | |
| III | 3 (9.7) | 11 (27.5) | |
Data were presented as count (percentage). Comparison was determined by Chi-square test or Wilcoxon rank sum test. p-value < 0.05 was considered significant (in bold). DEB-TACE, drug-eluting bead transarterial chemoembolization; cTACE, conventional transarterial chemoembolization; VAS, visual analogue scale; CINV, chemotherapy-induced nausea and vomiting.